| Autor: |
Rezende, Barbara Maximino, Athayde, Rayssa Maciel, Gonçalves, William Antônio, Resende, Carolina Braga, Teles de Tolêdo Bernardes, Priscila, Perez, Denise Alves, Esper, Lísia, Reis, Alesandra Côrte, Rachid, Milene Alvarenga, Castor, Marina Gomes Miranda e, Cunha, Thiago Mattar, Machado, Fabiana Simão, Teixeira, Mauro Martins, Pinho, Vanessa |
| Zdroj: |
The Journal of Experimental Medicine; November 2017, Vol. 214 Issue: 11 p3399-3415, 17p |
| Abstrakt: |
Leukotriene B4 (LTB4), a proinflammatory mediator produced by the enzyme 5-lipoxygenase (5-LO), is associated with the development of many inflammatory diseases. In this study, we evaluated the participation of the 5-LO/LTB4 axis in graft-versus-host disease (GVHD) pathogenesis by transplanting 5-LO–deficient leukocytes and investigated the effect of pharmacologic 5-LO inhibition by zileuton and LTB4 inhibition by CP-105,696. Mice that received allogeneic transplant showed an increase in nuclear 5-LO expression in splenocytes, indicating enzyme activation after GVHD. Mice receiving 5-LO–deficient cell transplant or zileuton treatment had prolonged survival, reduced GVHD clinical scores, reduced intestinal and liver injury, and decreased levels of serum and hepatic LTB4. These results were associated with inhibition of leukocyte recruitment and decreased production of cytokines and chemokines. Treatment with CP-105,696 achieved similar effects. The chimerism or the beneficial graft-versus-leukemia response remained unaffected. Our data provide evidence that the 5-LO/LTB4 axis orchestrates GVHD development and suggest it could be a target for the development of novel therapeutic strategies for GVHD treatment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
